The efficacy of direct-acting antivirals (DAAs) in the treatment of chronic hepatitis C (CHC) in liver transplant recipients is poorly understood, and several factors, including immunosuppression, drug interactions, elevated viraemia, and intolerance to ribavirin (RBV), can reduce cure rates. We conducted a real-life study on liver transplant recipients with CHC treated with a combination of sofosbuvir (SOF) and daclatasvir (DCV) or simeprevir (SIM), with or without RBV, followed-up for 12 to 24 weeks. The treatment effectiveness was assessed by determining the sustained virological response (SVR) rates at 12 or 24 weeks after the treatment cessation. Eighty-four patients were evaluated, with a mean age of 63.4 ± 7.4 years, HCV genotype 1 being the most prevalent (63.1%). Nineteen patients (22.7%) had mild fibrosis (METAVIR < F2) and 41 (48.8%) significant fibrosis (METAVIR ≥ F2). The average time between liver transplantation and the start of treatment was 4 years (2.1-6.6 years). The SOF + DCV regimen was used in 58 patients (69%). RBV in combination with DAAs was used in seven patients (8.3%). SVR was achieved in 82 patients (97.6%), and few relevant adverse events could be attributed to DAA therapy, including a patient who stopped treatment due to a headache. There was a significant reduction in ALT, AST, GGT and FA levels, or the APRI index after 4 weeks of treatment, which remained until 12/24 weeks post-treatment. DAA treatment of CHC in liver-transplanted patients achieved a high SVR rate and resulted in the normalization of serum levels of liver enzymes.
13 January 2025 in Revista de Epidemiologia e Controle de Infecção
Background and Objectives: Hepatitis C virus (HCV) infection is a relevant public health problem due to its prevalence and possible progression to cirrhosis and hepatocellular carcinoma. Although the use of direct-acting antivirals has decreased the incidence in recent years, identifying those infected remains a challenge for the elimination of HCV by 2030. The objective of this study was to estimate the prevalence of HCV antibody (anti-HCV), and describe the sociodemographic and behavioral risk factors associated with HCV infection in individuals in a small town in the Brazilian semi-arid region. Methods: Following a non-random sampling procedure, a cross-sectional study of 800 individuals in the waiting rooms of Basic Health Units (BHU) was conducted. After formal consent, a rapid screen test for anti-HCV (Immunochromatography)was carried out, and a questionnaire was applied to collect sociodemographic, clinical and risk behavior data. Results: Five tests were positive (0.62%; 95%CI 0.2 – 1.4%), four women and one man. All were over 60 years old (mean age of 69.4) and some risk behaviors in the past, use of glass syringes, surgery, or blood transfusion, were statistically associated with HCV exposure. Conclusion: In this study, a low prevalence of anti-HCV was observed, close to that estimated in recent studies. The antibody was more frequently positive in older individuals, aged over 60 years, who reported risky past behavior. Greater attention should be given to these individuals.